Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q3 loss of ($0.16), $0.07 worse than the analyst estimate of ($0.09).
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Commodities, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
